Inflammatory markers in women with reported benign gynecologic pathology: an analysis of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Cancer risk
Endometriosis
Inflammation
Leiomyoma
Ovarian cysts
Journal
Annals of epidemiology
ISSN: 1873-2585
Titre abrégé: Ann Epidemiol
Pays: United States
ID NLM: 9100013
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
18
05
2021
revised:
14
11
2021
accepted:
01
12
2021
pubmed:
16
12
2021
medline:
6
4
2022
entrez:
15
12
2021
Statut:
ppublish
Résumé
Associations between benign gynecologic pathologies and circulating inflammatory markers are unknown. Our goal was to evaluate self-reported history of benign gynecologic pathology and subsequent alterations in systemic inflammation. Using nested case-control studies from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, study-specific associations between self-reported history of benign ovarian cysts, uterine fibroids, and endometriosis with inflammatory marker concentrations were evaluated using logistic regression and combined using meta-analysis. Inflammatory markers associated with individual benign pathologies were mutually adjusted for one another to evaluate independent associations. Compared to women without a self-reported history of the pathology evaluated, benign ovarian cysts were associated with increased PAI-1 (OR [95% CI] 6.24 [2.53-15.39], P <.001) and TGF-β1 (3.79 [1.62-8.86], P =.002) and decreased BCA-1 (0.38 [0.19-0.73], P =.004). Uterine fibroids were associated with decreased CXCL11 (0.37 [0.22-0.63], P <.001) and VEGFR3 (0.40 [0.24-0.65], P <.001). Endometriosis was associated with increased SIL-4R (4.75 [1.84-12.26], P =.001). Self-reported history of benign gynecologic pathologies were associated with alterations in inflammatory markers that have been previously linked to cancer risk. Understanding interactions between benign gynecologic pathologies and the systemic immune system may help inform disease risk later in life.
Sections du résumé
BACKGROUND
Associations between benign gynecologic pathologies and circulating inflammatory markers are unknown. Our goal was to evaluate self-reported history of benign gynecologic pathology and subsequent alterations in systemic inflammation.
METHODS
Using nested case-control studies from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, study-specific associations between self-reported history of benign ovarian cysts, uterine fibroids, and endometriosis with inflammatory marker concentrations were evaluated using logistic regression and combined using meta-analysis. Inflammatory markers associated with individual benign pathologies were mutually adjusted for one another to evaluate independent associations.
RESULTS
Compared to women without a self-reported history of the pathology evaluated, benign ovarian cysts were associated with increased PAI-1 (OR [95% CI] 6.24 [2.53-15.39], P <.001) and TGF-β1 (3.79 [1.62-8.86], P =.002) and decreased BCA-1 (0.38 [0.19-0.73], P =.004). Uterine fibroids were associated with decreased CXCL11 (0.37 [0.22-0.63], P <.001) and VEGFR3 (0.40 [0.24-0.65], P <.001). Endometriosis was associated with increased SIL-4R (4.75 [1.84-12.26], P =.001).
CONCLUSIONS
Self-reported history of benign gynecologic pathologies were associated with alterations in inflammatory markers that have been previously linked to cancer risk. Understanding interactions between benign gynecologic pathologies and the systemic immune system may help inform disease risk later in life.
Identifiants
pubmed: 34906633
pii: S1047-2797(21)00344-6
doi: 10.1016/j.annepidem.2021.12.003
pmc: PMC8972075
mid: NIHMS1779310
pii:
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Subventions
Organisme : Intramural NIH HHS
ID : ZIA CP010128
Pays : United States
Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Références
Hum Reprod Update. 2014 Sep-Oct;20(5):702-16
pubmed: 24676469
Hum Genomics. 2013 Oct 30;7:22
pubmed: 24172014
Mutat Res. 2005 Dec 30;592(1-2):147-54
pubmed: 16054167
Clin Chim Acta. 2016 Oct 1;461:165-71
pubmed: 27527412
Semin Reprod Med. 2017 Jan;35(1):88-97
pubmed: 28049214
Gynecol Oncol. 2014 Nov;135(2):297-304
pubmed: 25158036
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1902-11
pubmed: 21715603
Blood. 2013 Aug 8;122(6):951-7
pubmed: 23814017
Int J Gynaecol Obstet. 2008 Mar;100(3):257-61
pubmed: 17976623
J Obstet Gynaecol Can. 2015 Feb;37(2):157-178
pubmed: 25767949
Fertil Steril. 2007 Feb;87(2):362-6
pubmed: 17094980
Cancer Immunol Res. 2014 Dec;2(12):1125-31
pubmed: 25480554
Ann Ital Chir. 2017;88:20-25
pubmed: 28447586
J Natl Cancer Inst. 2013 Dec 18;105(24):1871-80
pubmed: 24249745
J Natl Cancer Inst. 2014 Oct 01;106(11):
pubmed: 25274579
Acta Obstet Gynecol Scand. 1997 Jul;76(6):559-62
pubmed: 9246963
Am J Obstet Gynecol. 2010 Apr;202(4):373.e1-9
pubmed: 20096820
Endocrinology. 1999 Jun;140(6):2533-40
pubmed: 10342839
Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):710-718
pubmed: 33563649
Brief Bioinform. 2015 Jul;16(4):563-75
pubmed: 25256289
J Womens Health (Larchmt). 2013 Oct;22(10):807-16
pubmed: 24033092
Cell Tissue Res. 2016 May;364(2):415-27
pubmed: 26613601
Carcinogenesis. 2011 Mar;32(3):296-304
pubmed: 21149644
Mol Med Rep. 2017 Jun;15(6):4100-4108
pubmed: 28487957
Int J Cancer. 2017 Feb 1;140(3):600-610
pubmed: 27770434
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Carcinogenesis. 2009 Jul;30(7):1073-81
pubmed: 19468060
Cancer Res. 2019 Oct 15;79(20):5442-5451
pubmed: 31462430
Stem Cells Int. 2018 May 13;2018:1716246
pubmed: 29861738
J Clin Oncol. 2016 Aug 20;34(24):2888-98
pubmed: 27325851
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Psychoneuroendocrinology. 2019 Nov;109:104422
pubmed: 31519314
Fertil Steril. 2013 Jul;100(1):178-93
pubmed: 23557758
Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S
pubmed: 11189684
Biomed Pharmacother. 2018 Sep;105:83-94
pubmed: 29852393
Int J Mol Med. 2007 Jun;19(6):909-13
pubmed: 17487423
Fertil Steril. 1982 Dec;38(6):667-72
pubmed: 6216124
Obstet Gynecol. 2018 Mar;131(3):557-571
pubmed: 29420391
Am J Obstet Gynecol. 2008 Jan;198(1):34.e1-7
pubmed: 17981254
Exp Mol Pathol. 2015 Aug;99(1):163-72
pubmed: 26079660
Front Endocrinol (Lausanne). 2019 Jul 12;10:471
pubmed: 31354634
Obstet Gynecol. 1988 Mar;71(3 Pt 1):319-22
pubmed: 3347414
Am J Obstet Gynecol. 1997 Mar;176(3):572-9
pubmed: 9077609